Saccharomyces boulardii (S. boulardii), as the sole fungal probiotic, exhibits significant therapeutic efficacy in treating various gastrointestinal disorders. In contrast to traditional bacterial probiotic preparations, S. boulardii stands out for its diverse array of biological activities, including anti-inflammatory, antibacterial, enzymatic, metabolic, and anti-toxin properties. S. boulardii is not indigenous to the human microbiome and is resistant to gastric acid, ensuring its stability and tolerability. Clinical research indicates that S. boulardii offers a positive therapeutic effect in treating gastrointestinal disorders such as acute diarrhea, antibiotic-induced diarrhea, inflammatory bowel disease, and irritable bowel syndrome, while also demonstrating high oral safety. Although the specific mechanisms of action of S. boulardii remain unclear, its clinical efficacy has been widely recognized. This article provides an overview of the advancements in S. boulardii’s application in treating childhood gastrointestinal diseases, serving as a reference for future research directions and clinical applications of this fungus.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |